phase i/ii dose-escalation study of 225ac-j591 in progressive mcrpc
Published 3 years ago • 211 plays • Length 5:47Download video MP4
Download video MP3
Similar videos
-
5:23
phase i dose-escalation study of fractionated dose 225ac j591 for mcrpc
-
1:11
scott tagawa, md, shares results of phase 1 dose escalation study of 225ac-j591 in mpc patients
-
7:14
psma-targeted alpha emitter 225ac-j591 for mcrpc
-
2:20
phase i trial of 225ac-j591 in metastatic castration-resistant prostate cancer
-
8:23
results from a phase i study of amg 160
-
4:02
precision medicine in prostate cancer
-
2:06:21
pcl #62 the current & future landscape - metastatic castrate resistant prostate cancer-oliver sartor
-
5:12
using lutetium-177 treatment for prostate cancer | ask a prostate expert, mark scholz, md
-
2:48
phase i sipipi in progressive mcrpc - video abstract id 122497
-
2:04
phase i/ii trial of 177lu−j591 and 177lu−psma−617 in mcrcp
-
1:37
results of phase i study reach primary end point for mcrpc
-
2:25
phase i trial of arx517, an anti-psma adc, in mcrpc
-
7:26
targeting psma in mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
19:02
prof. t. fischer at ecr 2018 - "mri-us fusion for diagnostic assessment of the prostate..."
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
4:05
presto study
-
7:02
overview of prostate cancer treatment--active surveillance or surgery?
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
0:31
a prostate disease solution | tulsa procedure
-
2:11
8 evaluating the calculated dose distribution in prostate imrt
-
2:02
pcss - prostate cancer test differences